Greco, Céline <br/><br/>
Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations.  [electronic resource] 

 -  JAMA dermatology  02 2020 
 - 191-195 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2168-6084 
<br/><br/><label>Standard No.: </label>10.1001/jamadermatol.2019.4126  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Disease Progression<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Keratoderma, Palmoplantar--drug therapy<br/>Male<br/>Mutation<br/>Protein Kinase Inhibitors--administration & dosage<br/>Syndrome<br/>TRPV Cation Channels--genetics